Zacks Research Weighs in on Bausch Health Companies Inc.’s Q4 2024 Earnings (TSE:BHC)

Bausch Health Companies Inc. (TSE:BHC) – Analysts at Zacks Research upped their Q4 2024 earnings estimates for shares of Bausch Health Companies in a report issued on Tuesday, June 25th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $1.51 for the quarter, up from their previous forecast of $1.49. The consensus estimate for Bausch Health Companies’ current full-year earnings is $4.85 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q1 2025 earnings at $1.14 EPS, Q2 2025 earnings at $1.27 EPS, Q3 2025 earnings at $1.55 EPS, FY2025 earnings at $5.74 EPS, Q1 2026 earnings at $1.48 EPS and FY2026 earnings at $6.95 EPS.

Bausch Health Companies Price Performance

TSE:BHC opened at C$9.27 on Thursday. The company has a 50-day moving average of C$9.66 and a 200-day moving average of C$10.97. The company has a market capitalization of C$3.40 billion, a price-to-earnings ratio of -5.49, a PEG ratio of 0.21 and a beta of 0.90. Bausch Health Companies has a 52 week low of C$8.32 and a 52 week high of C$15.43. The company has a debt-to-equity ratio of 7,583.76, a quick ratio of 0.58 and a current ratio of 1.23.

Bausch Health Companies (TSE:BHC) last posted its quarterly earnings results on Thursday, May 2nd. The company reported C$0.80 earnings per share (EPS) for the quarter, missing the consensus estimate of C$1.02 by C($0.22). The company had revenue of C$2.90 billion during the quarter, compared to analyst estimates of C$2.98 billion. Bausch Health Companies had a negative return on equity of 686.52% and a negative net margin of 5.07%.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.